Abstract: The present invention concerns the development of a model to evaluate active substances targeting the epidermis. It more particularly relates to the preparation of mixed spheroids of melanocytes and keratinocytes reproducing cell interactions occurring in the epidermis, to the spheroids as such and to the uses thereof.

Abstract: A peptide sequence includes a fragment of at least 10 amino acids derived from the following SEQ ID NO:1: DRKMEVEELSpPLALGRFSL SEQ ID NO:1 wherein the serine residue in position 10 is phosphorylated, the above-mentioned fragment containing the phosphorylated serine residue. A polyclonal or monoclonal antibody capable of identifying a peptide sequence as defined above is also disclosed.

Abstract: The present invention relates to a peptide sequence characterized in that it comprises or is constituted by a fragment of at least approximately 10 amino acids originating from the following sequence SEQ ID NO: 1: TPVQNKRRRSpVTPPEEQQE SEQ ID NO: 1 in which the serine residue in position 10 is phosphorylated, said above-mentioned fragment containing said phosphorylated serine residue. The present invention also relates to a polyclonal or monoclonal antibody capable of recognizing a peptide sequence as defined above.

Abstract: The invention concerns novel cdc25 phosphatase inhibitors, and in particular cdc25-C, which correspond to the general formula (I) wherein: A represents a carbocyclic aryl radical optionally substituted 1 to 3 times by one or more radicals independently selected among a halogen atom and an alkyl, hydroxy, alkoxy, alkylthio or NR1R2 radical wherein R1 and R2 represent a hydrogen atom or an alkyl radical or R1 and R2 form together with the nitrogen atom a heterocycle of 4 to 7 members comprising 1 to 2 heteroatoms, the members required to complete the heterocycle being selected independently among the CR3R4—, —O—, —S and NR5-radicals, R3 and R4 representing independently each time they are involved a hydrogen atom or an alkyl, hydroxy, alkoxy, amino, alkylamino or dialkylamino radical, and R5 representing independently each time it is involved a hydrogen atom or an alkyl radical, or A represents a phenyl radical substituted by a phenyl radical optionally substituted 1 to 3 times by one or more radicals selected

Abstract: A method of inhibiting cdc25 phosphatases in warm-blooded animals comprising administering to warm-blooded animals in need thereof an effective amount of a compound of the formula wherein the substituents are defined as in the specification.

Abstract: A method of inhibiting cdc25 phosphatases in warm-blooded animals comprising administering to warm-blooded animals in need thereof an effective amount of a compound of the formula wherein the substituents are defined as in the specification.

Abstract: The invention concerns novel cdc25 phosphatase inhibitors, and in particular cdc25-C, which correspond to the general formula (I) wherein: A represents a carbocyclic aryl radical optionally substituted 1 to 3 times by one or more radicals independently selected among a halogen atom and an alkyl, hydroxy, alkoxy, alkylthio or NR1R2 radical wherein R1 and R2 represent a hydrogen atom or an alkyl radical or R1 and R2 form together with the nitrogen atom a heterocycle of 4 to 7 members comprising 1 to 2 heteroatoms, the members required to complete the heterocycle being selected independently among the CR3R4—, —O—, —S and NR5-radicals, R3 and R4 representing independently each time they are involved a hydrogen atom or an alkyl, hydroxy, alkoxy, amino, alkylamino or dialkylamino radical, and R5 representing independently each time it is involved a hydrogen atom or an alkyl radical, or A represents a phenyl radical substituted by a phenyl radical optionally substituted 1 to 3 times by one or

Abstract: The invention concerns a method for obtaining human cdc 25B1, cdc25B2, cdcB3 and cdc25C phosphatases. More particularly, the invention concerns a protein for fusion between human cdc25B1, cdc25B2, cdcB3 or cdc25C phosphatase and the maltose binding protein (MBP) of Escherichia coli, the DNA sequence coding for said fusion protein, a method for preparing said fusion protein and a method for identifying human cdc25B1, cdc25B2, cdcB3 or cdc25C protein modulators.